INTRODUCTION {#s1}
============

Although the incidence of gastric cancer has declined recently, gastric cancer still remains one of the most common cancers. Nearly one million new gastric cancer cases are diagnosed every year \[[@R1]\]. Gastric cancer has been the second leading cause of cancer-related deaths all over the world \[[@R2]\], and has a 5-year survival of 28% or less \[[@R3]\]. Curative resection, as a standard surgery procedure, has been widely used in the treatment of gastric cancer \[[@R4]\].

However, prognosis of gastric cancer patients varies due to individual factors. Thus, a consensus standard is needed for prognostic prediction and individualized therapy scheduling. In 2010, the 7^th^ edition of the American Joint Committee on Cancer (AJCC) tumor--node-metastasis (TNM) staging system was published. It is a conventional method for prognostic prediction of gastric cancer \[[@R5]\]. Unfortunately, survival could usually vary from each other even in patients with the same AJCC stage. In fact, clinicopathological parameters like gender, age, tumor size, differentiation, and adjuvant chemotherapy were not involved in this system, and prognostic differences may be caused by these ignored but significant characteristics, which could affect the final survival status to some extent. Therefore, a more refined staging system considering both the tumor characteristics and host status is needed.

Nomogram, a better estimation of the prognosis, included aforementioned basic prognostic factors, has been developed for survival prediction in many other cancers \[[@R6]--[@R10]\]. Recently, several nomograms have also been established and validated in gastric cancer \[[@R11]--[@R15]\]. These prognostic models based on clinicopathological characteristics could predict the survival of gastric cancer patients more accurately compared with the AJCC TNM staging system.

However, metastatic lymph nodes ratio (mLNR), one of the most reliable predictors for curatively resected gastric cancer patients, has not been included in previous nomograms \[[@R16]\]. The mLNR, defined as the ratio of the metastatic lymph divided by the retrieved lymph nodes, showed significant superiority in minimizing 'stage migration' and has been demonstrated to be an independent prognostic factor in gastric cancer \[[@R17]--[@R20]\].

In the current study, we constructed a nomogram based on mLNR to predict the individualized survival of gastric cancer patients underwent curative resection. We also evaluated the significance of the nomogram in the patients with examined lymph nodes (TLN)≤15 for the first time. We supposed that the tumor--positive node ratio-metastasis (TRM)-based nomogram may work better in prognostic prediction when compared with the tumor--node-metastasis (TNM)-based nomogram and the AJCC staging system.

RESULTS {#s2}
=======

Patient demographics and outcomes {#s2_1}
---------------------------------

We retrospectively studied 2,205 patients underwent curative resection in Sun Yat-sen University Cancer Center from 2000 to 2012. Patients in the training set (n=1,470) and the internal validation set (n=735) were analyzed respectively. The mean age was 57.1±12.0 and 57.7±11.6 for training set and validation set separately. There were 1,002 men in the training set and 496 men in the validation set. 36.6% of the patients died by the time of this report. The 5-year overall survival was 55.3%. The median follow-up was 49.4 months in training set and 22.6 months in validation set. The mean number of examined lymph nodes was 20.5±12.0 and 25.8±11.8, and the mean number of positive lymph nodes was 5.8±7.7 and 6.0±7.9 in training and validation set respectively. The clinicopathologic characteristics for the training set and validation set were listed in Table [1](#T1){ref-type="table"} and the baseline characteristics for the two external validations were listed in Table [2](#T2){ref-type="table"}.

###### Characteristics of training set and validation set

                          Training set (n=1470)   Validation set (n=735)         
  ----------------------- ----------------------- ------------------------ ----- ------
  Age (years)                                                                    
   Median                 57.1±12.0               57.7±11.6                      
   Range                  19 to 89                16 to 86                       
  Sex                                                                            
   Male                   1002                    68.2                     496   67.5
   Female                 468                     31.8                     239   32.5
  Tumor size (cm)                                                                
   \< 2                   78                      5.3                      54    7.3
   2-4                    433                     29.5                     275   37.4
   4-6                    527                     35.9                     224   30.5
   6-8                    297                     20.2                     126   17.1
   ≥ 8                    135                     9.1                      56    7.6
  Tumor location                                                                 
   Upper                  662                     45.0                     324   44.1
   Middle                 264                     18.0                     113   15.4
   Lower                  544                     37.0                     298   40.5
  Pathology type                                                                 
   Differentiated         1110                    75.5                     653   88.8
   Undifferentiated       360                     34.5                     82    11.2
  Depth of invasion                                                              
   Mucosa or submucosa    122                     8.3                      110   15.0
   Proper muscle          169                     11.5                     90    12.2
   Subserosa              231                     15.7                     285   38.8
   Serosa                 765                     52.0                     210   28.6
   Adjacent invasion      183                     12.4                     40    5.4
  Positive LN (Mean±SD)   5.8±7.7                 6.0±7.9                        
  Total LN (Mean±SD)      20.5±12.0               25.8±11.8                      
   ≤ 15                   578                     39.3                     158   21.5
   ≥ 16                   892                     60.7                     577   78.5
  mLNR (Mean±SD)          0.3±0.3                 0.2±0.3                        
  AJCC Stage                                                                     
   IA                     95                      6.5                      73    9.9
   IB                     88                      6.0                      67    9.1
   IIA                    119                     8.1                      78    10.6
   IIB                    222                     15.1                     125   17.0
   IIIA                   194                     13.2                     113   15.4
   IIIB                   327                     22.2                     149   20.3
   IIIC                   425                     28.9                     130   17.7

Abbreviation: LN: lymph node; mLNR: metastatic lymph node ratio; AJCC: American Joint Committee on Cancer.

###### Characteristics of validation sets

                          JXCH-validation set (n=602)   SEER-validation set (n=3317)          
  ----------------------- ----------------------------- ------------------------------ ------ ------
  Age (years)                                                                                 
   Median                 59.0±10.7                     69.0±12.0                             
   Range                  23 to 83                      20 to 90                              
  Sex                                                                                         
   Male                   434                           72.1                           2186   65.9
   Female                 168                           27.9                           1131   34.1
  Tumor size (cm)                                                                             
   \< 2                   49                            8.1                            533    16.1
   2-4                    227                           37.7                           1076   32.4
   4-6                    182                           30.2                           864    26.1
   6-8                    116                           19.3                           518    15.6
   ≥ 8                    28                            4.7                            326    9.8
  Tumor location                                                                              
   Upper                  117                           19.5                           1157   34.9
   Middle                 161                           26.7                           1018   30.7
   Lower                  324                           53.8                           1142   34.4
  Pathology type                                                                              
   Differentiated         172                           28.6                           248    7.5
   Undifferentiated       430                           71.4                           3069   92.5
  Depth of invasion                                                                           
   Mucosa or submucosa    94                            15.6                           707    21.3
   Proper muscle          123                           20.4                           565    17.0
   Subserosa              116                           19.3                           1460   44.0
   Serosa                 149                           24.8                           437    13.2
   Adjacent invasion      120                           19.9                           148    4.5
  Positive LN (Mean±SD)   4.72±8.0                      2.86±5.24                             
  Total LN (Mean±SD)      27.65±16.1                    17.77±12.56                           
   ≤ 15                   132                           21.9                           1744   52.6
   ≥ 16                   470                           78.1                           1573   47.4
  mLNR (Mean±SD)          0.19±0.32                     0.17±0.25                             
  AJCC Stage                                                                                  
   IA                     79                            13.1                           516    15.6
   IB                     97                            16.1                           370    11.2
   IIA                    66                            11.0                           462    13.9
   IIB                    80                            13.3                           619    18.7
   IIIA                   33                            5.5                            570    17.2
   IIIB                   107                           17.8                           508    15.3
   IIIC                   140                           23.3                           272    8.2

Abbreviation: LN: lymph node; mLNR: metastatic lymph node ratio; AJCC: American Joint Committee on Cancer.

Development and validation of the nodes ratio staging system {#s2_2}
------------------------------------------------------------

Based on the SYSUCC data set, we categorized all the included patients into two groups (TLN ≥16 and TLN ≤15), Patients with examined lymph nodes ≥16 showed better prognosis than those ≤15 with respective TNM categories (p\<0.001) (Figure [1A](#F1){ref-type="fig"}). Node-negative patients with 15 or less retrieved has no difference with mLNR (0 to 1/15) patients for overall survival (p=0.405), and node-negative patients with 16 or more exhibited significantly better survival than mLNR 0 with TLN ≤15 (p\<0.001) (Figure [1B](#F1){ref-type="fig"}). Thus, the mLNR 1 was defined as mLNR (0 to 1/15) and node-negative patients with 15 or less retrieved, while the node-negative patients with 16 or more were classified as mLNR 0. According to X-tile, the cutoff points of 25% and 47% were used for the other patients. ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) We also analyzed the survival of the patients by the Kaplan Meier method and survival curves, and found the survival differences within respective categories were more obvious in the TRM than that in TNM staging system (Figure [1C, 1D](#F1){ref-type="fig"}).

![Impact of mLNS and mLNR staging on gastric cancer-related survival respectively\
**(A)** Overall survival according to AJCC N stage (mLNS), stratified by the number of examined nodes (≤15 and ≥16). **(B)** Overall survival of node-negative patients with 15 or less retrieved, mLNR (0 to 1/15) and node-negative patients with 16 or more retrieved. **(C)** Overall survival according to mLNS stage. **(D)** Overall survival according to mLNR stage. Abbreviation: mLNS, metastatic lymph node stage; mLNR, metastatic lymph node ratio.](oncotarget-08-45585-g001){#F1}

Independent risk factors in the training set {#s2_3}
--------------------------------------------

Variables were transformed and examined to fit the Cox Proportion Hazard Regression. In the univariate analysis, age, gender, tumor location, tumor size, patho-logical type, depth of invasion (pT), N stage (mLNS), mLNR and total number of examined lymph nodes (TLN) were statistically significant prognostic factors. Significant variables were included into the multivariate analysis by the forward method. In multivariate analyses, age, tumor location, pathological type, pT and TLN were identified as the independent risk factors for overall survival (OS) (Table [3](#T3){ref-type="table"}), while gender and tumor size were excluded. Both mLNS and mLNR were found to be statistically significant (p\<0.001).

###### Multivariate analysis of the training set

                         Model-TNM   Model-TRM                                         
  ---------------------- ----------- --------------- --------- ------- --------------- ---------
  Age                    1.02        1.01 to 1.03    \<0.001   1.02    1.01 to 1.03    \<0.001
  Location                                           \<0.001                           \<0.001
   Lower                 ref                                   ref                     
   Middle                1.37        1.09 to 1.73              1.43    1.13 to 1.81    
   Upper                 1.57        1.31 to 1.90              1.55    1.29 to 1.86    
  Pathological type      1.25        1.05 to 1.50    0.028     1.23    1.03 to 1.46    0.022
  NO. of examined LNs    0.97        0.96 to 0.98    0.013                             
  Depth of invasion                                  \<0.001                           \<0.001
   Mucosa or submucosa   ref                                   ref                     
   Proper muscle         4.76        1.69 to 13.41             5.01    1.78 to 14.11   
   Subserosa             6.13        2.23 to 16.86             6.11    2.22 to 16.81   
   Serosa                10.84       4.00 to 29.36             10.69   3.94 to 28.98   
   Adjacent invasion     15.97       5.83 to 43.75             16.18   5.90 to 44.36   
  mLNR                                                                                 \<0.001
   0                                                           ref                     
   1                                                           1.49    0.98o 2.27      
   2                                                           2.14    1.44 to 3.18    
   3                                                           3.41    2.31 to 5.03    
   4                                                           5.90    4.04 to 8.61    
   5                                                           6.56    4.19 to 10.27   
  mLNS                                               \<0.001                           
   0                     ref                                                           
   1                     1.87        1.40 to 2.49                                      
   2                     2.54        1.94 to 3.33                                      
   3a                    4.26        3.24 to 5.60                                      
   3b                    7.06        5.03 to 9.90                                      

Abbreviation: HR: hazard ratio; mLNR: metastatic lymph node ratio; mLNS: metastatic lymph node stage.

Construction and validation of the nomogram {#s2_4}
-------------------------------------------

Two potential nomograms, TNM and TRM-based were constructed respectively based on the training set. Figure [2](#F2){ref-type="fig"} shows predicting 1-year, 3-year and 5-year survival of the nomogram established based on the TRM variables. By adding up the points identified on the points scale, the nomogram can predict the likehood of 1-year, 3-year and 5-year OS for individual patient according to the total score showed in the bottom scale. The C-index for TNM-based model exhibited superior to the AJCC-TNM staging system (0.73, 95%CI: 0.69 to 0.78 vs 0.69, 95%CI: 0.65 to 0.74, p\<0.001). Furthermore, when the mLNS was replaced by mLNR, the C-index of the TRM model nomogram significant increased from 0.73 to 0.76 (p\<0.001). It indicated that the nomogram based mLNR was the optimal model, compared with TNM-nomogram and AJCC-TNM staging system.

![Nomogram predicting 1-year, 3-year and 5-year OS for resectable gastric cancer patients after curative resection\
Abbreviation: mLNR: metastatic lymph node ratio.](oncotarget-08-45585-g002){#F2}

In addition, the calibration plots were separately performed by the training set, internal validation set and primary cohort. As shown in the Figure [3](#F3){ref-type="fig"}, the calibration plot shows that the predicted 3-year and 5-year overall survival corresponded closely with the actual survival estimated by the Kaplan-Meier method (Figure [3A, 3B, 3E, 3F](#F3){ref-type="fig"}). Since patients with examined lymph nodes ≥16 survives better than those ≤15 (p\<0.001) (Figure [1A](#F1){ref-type="fig"}), we further validated our results in both TLN≥16 (n=1,469) and ≤15 (n=736) groups by using these three models (Figure [3C, 3D](#F3){ref-type="fig"}). Notably, in the TLN ≥16 group, the TRM-based nomogram has the higher C-index value (0.77) than TNM-based nomogram (0.75) and AJCC-TNM staging system (0.72) (p value\<0.001). The results was similar in the TLN≤15 group (TRM-based nomogram, TNM-based nomogram and AJCC-TNM staging system with the C-index were 0.75, 0.73 and 0.70, respectively) (p\<0.001). Figure [4A](#F4){ref-type="fig"} shows the 5-year survival in different stages predicted by the AJCC TNM Staging system, with no good discrimination between patients with stage IB and IIA. However, within respective TNM categories, a wide range of predicted survival could be identified by the nomogram (Figure [4B](#F4){ref-type="fig"}).

![The calibration curves for predicting patients overall survival at 5-year in the training set\
**(A)**, validation set with TLN ≤ 15 **(B)**, validation set with TLN ≥ 16 **(C)**, validation set **(D)** and predicting overall survival at 3-year **(E)**, 5-year **(F)** in primary cohort. The X-aixs represents the nomogram-predicted survival, and the actual survival is plotted on the Y-axis. The dotted line represents the ideal correlationship between predicted and actual survival.](oncotarget-08-45585-g003){#F3}

![**(A)** Overall survival of primary cohort according to the 7th edition AJCC staging system; **(B)** Distribution of nomogram-predicted 5-year overall survival based on the 7th edition of AJCC staging system.](oncotarget-08-45585-g004){#F4}

In the JXCH validation set, the C-index of the TRM-based nomogram was 0.76, (95%CI: 0.72 to 0.80), higher than that of the TNM-based nomogram and the 7^th^ AJCC system (0.74, 95%CI: 0.70 to 0.78 and 0.73, 95%CI: 0.69 to 0.76) (p\<0.001). Consistently, TRM-based nomogram maintained the optimal discrimination both in the TLN ≥16 group (C-index: 0.74, 95%CI: 0.70 to 0.78 for TRM-based nomogram, C-index: 0.73, 95%CI: 0.68 to 0.77 for TNM-based nomogram and C-index: 0.72, 95%CI: 0.68 to 0.76 for 7^th^ AJCC system) (p\<0.001) and TLN≤15 group (C-index: 0.78, 95%CI: 0.70 to 0.84 for TRM-based nomogram, C-index: 0.77, 95%CI: 0.71 to 0.84 for TNM-based nomogram and C-index: 0.76, 95%CI: 0.69 to 0.82) (p\<0.001). [Supplementary Figure 2](#SD1){ref-type="supplementary-material"} shows the calibration plots of the TRM-based nomogram.

Similarily, in the SEER validation set, TRM-based nomogram still had a superior discrimination than the other two staging systems (C-index: 0.75, 95%CI: 0.74 to 0.77 for TRM-based nomogram, C-index: 0.73, 95%CI: 0.72 to 0.75 for TNM-based nomogram and C-index: 0.70, 95%CI: 0.69 to 0.72 for the 7^th^ AJCC system) (p\<0.001). Consistent results were got in the two subgroups (the TLN ≥16 group and the TLN≤15 group), the TRM-based nomogram kept the optiaml C-index value (0.74 for TLN ≥16 group and 0.76 for TLN≤15 group), higher than those of the other systems (all p value\<0.001). Considering the longest follow up time of SEER data was 47 months, 5-year calibration was not accessible in our study. [Supplementary Figure 3](#SD1){ref-type="supplementary-material"} shows 1-year and 3-year calibration plots of the TRM-based nomogram.

DISCUSSION {#s3}
==========

In the present study, a large number of 2,205 gastric cancer patients underwent curative resection were involved to develop a nomogram based on mLNR, which could predict the survival better than the current TNM-based nomogram and AJCC TNM staging system. Especially, we firstly evaluated the significance of the nomogram in the patients with TLN ≤15 and validated the nomogram based both on eastern and western populations.

Previously, we had found that the mLNR was a better independent prognostic predictor of gastric cancer patients compared with mLNS. A staging system based on mLNR should be considered to be an alternative to the 7th AJCC TNM staging system \[[@R19], [@R21]\]. Similar results were achieved in many other studies. For example, in 2013, Ala et al performed a study about gastric cancer patients and figured out that the staging system based on mLNR was superior to TNM system \[[@R22]\]. Li X et al retrospectively reviewed a total 535 gastric cancer patients at different pT stages, and found that mLNR had a much better prediction ability comparable to that of pN stage in 2015 \[[@R23]\]. Consistently, in the current study, the nodes ratio staging system successfully stratified patients more obviously according to their survival risks, compared to the nodes staging system, which further showed that the TRM staging system worked better in prognostic prediction than the TNM staging systems.

Furthermore, we developed a nomogram based on mLNR along with other clinicopathologic parameters. In the training set, TNM-based and TRM-based nomogram were constructed respectively. We found that the TNM-based nomogram predicts survival more accurate than the AJCC TNM Staging system (C-index value: 0.73 vs 0.69, p\<0.001). Interestingly, when the new factor mLNR was included in the nomogram, the TRM-based nomogram had a much higher C-index value (C-index=0.76) and predicted survival more accurately than the other two approaches. in the internal validation set, the calibration plot shows that the predicted 3-year and 5-year overall survival corresponded closely with the actual survival estimated by the Kaplan-Meier method. Additionally, external validations further indentified the discrimination of our TRM-based nomogram, it maintained the optimal C-index and calibration plot in the JXCH and SEER validation sets.

Since a least number of 15 lymph nodes was necessary for appropriate staging of gastric cancer according to the 7^th^ AJCC system, it is difficult to assess the prognosis of gastric cancer patients with insufficient nodes retrieved \[[@R5]\]. In fact, the significance of the nomogram has not ever been evaluated in the patients with TLN≤15. In this study, we take into consideration the influence of the TLN to the accuracy of prognostic prediction for the first time. Primary cohort and validation sets were stratified by the cutoff point (TLN ≥16 and TLN ≤15) and analyzed by the three aforementioned staging system respectively. Still, we found that the TRM-based nomogram had the much higher C-index than other models whenever in TLN ≥16 or TLN ≤15 group (p\<0.001). It suggests that the discrimination power of nomogram based on mLNR is superior to the TNM-based nomogram and the 7^th^ AJCC staging system. Clearly, our study showed that a TRM-based nomogram could predict survival for gastric cancer more accurately regardless of TLN.

There may be several potential reasons for the superiority of nomogram based on the mLNR. Firstly, the number of metastatic lymph nodes is associated with the surgical and pathologic procedure and varies with the efforts and techniques of the pathologists and surgeons. Improper stage might be acquired due to the insufficient lymph nodes retrieved in surgery, leading to 'stage migration' \[[@R24]\]. Secondly, there may be the possibilities of micro-metastases in those negative lymph nodes. Patients with micro-metastases usually share a higher risk of recurrence \[[@R25]\]. In this study, we not only included clinicpathological variables like age, tumor location, pT, TLN and mLNS, but also the newly proposed mLNR, which remains excellent accuracy regardless of total number of the examined lymph nodes \[[@R25]\]. Finally, both professional doctors and gastric cancer patients could assess the individualized survival by performing such a costless and easily accessible scoring system.

Note that the most critical argument for a predictive model is the applicability. We performed our nomogram by a multi-institution method, based on both eastern and western populations. To establish a novel nomogram ignoring the influences of factors like improvements of surgical technique, nursing, medication and the quality of care in different periods, the internal validation set was not assigned by commonly used conventional random method but by the time sequence, as our prior study \[[@R26]\]. Actually, it is unsatisfactory to assess a nomogram by only internal validation because of the heterogeneity in data record and collection, which could be well solved by external validation. Subsequently, to justify its clinical usefulness, an external validation based on anther hospital in Jiangxi (JXCH validation set) was also performed to avoid selective bias and identify its universal applicability \[[@R27]\]. Mover, a high quality database, SEER database was also used for validation. Unlike common database, it is a national collaboration program by the National Cancer Institute, containing nearly 3,000,000 cases from various regions and covers 26% American population\'s cancer incidence and survival data, which is reliable for data quality. Surprisingly, our nomogram showed satisfactory predictive value not only in populations in China, but also in the Americans. The comprehensive validations further ascertained the applicability of our model in different populations.

Despite the satisfactory results in our studies, there are also some limitations in our studies. First, the current study involves only patients underwent curative resection, whether the results was suitable for other surgical strategies was not sure. Second, as a retrospective study, more proven significant variables such as Lauren classification, post-operative chemotherapy, radiation therapy, physical status, genomic characteristics are not available in our study, further investigations are needed in the future.

In summary, based on the training and validation sets, we analyzed the survival using three kinds of staging system separately. For the first time, we demonstrated that the TRM-based nomograms predicts the survival of gastric cancer patients more accurately than previous TNM-based nomogram and AJCC TNM staging system regardless of the number of examined lymph nodes. Given that prognosis remains uncertain and continues to be debated for gastric cancer, especially for the patients with TLN ≤15, this nomogram will be very useful when we evaluating adjuvant treatment options.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

We retrospectively reviewed a total number of 2,205 patients (Primary cohort) between 2000 and 2012, all of who were hospitalized in the Department of Gastropancreatic surgery, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China. The patients enrolled met the following criteria: patients with pathologically or histologically proven gastric cancer; no history of preoperative neo-adjuvant chemotherapy; no distant metastasis; underwent curative resection; R0 resection (No macroscopic and microscopic residual tumor); no history of other malignancies.

Additionally, Two external data sets met the aforementioned criteria (Jiangxi Provincial Cancer Hospital (JXCH) data set, from 2008 to 2013, n=602 and the Surveillance, Epidemiology, and End Results (SEER) data set, from 2010 to 2013, n=3,317) were also analyzed for validation.

Factors {#s4_2}
-------

Factors like host status (age, gender), tumor characteristics (size, location, histological type, depth of invasion, number of metastatic lymph nodes, and total number of examined lymph nodes (TLN)) and follow-up data (follow up duration and survival status) were reviewed in our data set. The tumor size was measured as the widest diameter and grouped by the cutoff points of 2cm, 4cm, 6cm and 8cm. The tumor location was defined as upper third, middle third and lower third based on the main center of the lesion. As for the histological type, papillary, tubular adenocarcinoma and mucinous adenocarcinoma were included in the differentiated type, while signet ring cell carcinoma and small cell carcinoma were defined as the undifferentiated type. The classification of the depth of invasion and lymph node metastasis (mLNS) were performed according to the 7th AJCC TNM staging system \[[@R5]\].

Follow up {#s4_3}
---------

Patients were followed up by post-operative clinical and laboratory examinations per 3 months during the first 2 years, per 6 months from the third year to the fifth year and annually until he/she died. The follow-up duration was defined as the interval between the surgery and last follow up, and overall survival time was defined as the time between the surgery and all-cause death.

Development of the nodes ratio staging system {#s4_4}
---------------------------------------------

For the training set, we classified the node-negative patients with 15 or less as mLNR 1, and the node-negative patients with 16 or more as mLNR 0 \[[@R5]\]. We categorized the node-positive patients into 5 groups according to the following criteria: mLNR 1: 0\<mLNR≤1/15; mLNR 2: 1/15\<mLNR≤25%; mLNR 3: 25%\<mLNR≤47%; mLNR 4: 47%\<mLNR≤99%; mLNR 5: mLNR= 100%. The cutoff points were identified by the X-tile software version 3.6.1 (Yale University School of Medicine, New Haven, CT, USA) \[[@R28]\]. Thus, a new TRM staging system was constructed based on our mLNR stage.

Construction of the nomogram {#s4_5}
----------------------------

For the development and internal validation of the nomogram, the 2,205 population was divided in two groups. Patients who underwent curative resection before December 31, 2008 were assigned to the training set (n=1,470) and patients who underwent surgery between January 1, 2009 and December 31, 2012 (n=735) were selected as the internal validation set. By the Multivariate Cox Proportional Hazards Regression analysis of the training set, the independent risk factors were identified. And then, nomogram based on the independent risk factors was constructed. In this study, we built TNM-based and TRM-based nomogram separately. The former nomogram was constructed mainly based on the number of the examined lymph nodes, which is the same as the prior studies \[[@R11], [@R13]\]. However, the latter based on mLNR, is a novel model.

Validation of the nomogram {#s4_6}
--------------------------

The performance of the nomogram was evaluated by discrimination and calibration using internal (SYSUCC, n=735) and two external (JXCH validation set, n=602 and SEER validation set, n=3,317) validation sets. Regarding discrimination, Harrell\'s C-index was used, which is appropriate for censored data and similar to the area under the receiver operating characteristic (ROC) curve \[[@R29]\]. C-index provides the probability between the observed and predicted OS. Generally, the C-index acts as a measure of the accuracy of a nomogram, and a value more than 0.75 usually indicates relatively good discrimination (the closer it is to 1.0, the more accurate it is) \[[@R30]\]. For calibration, the data was divided into several groups based on the probabilities calculated by the nomogram predictive model. Subsequently, predicted probabilities produced by the nomogram was compared with actual probabilities by the Kaplan Meier method. H-L chi-square statistic and bootstrapping correction were used for this purpose.

P value\<0.05 was considered to be statistically significant. All analyses were performed by the software statistical package for social sciences version 20.0 (SPSS, Chicago, IL) and the package of *rms* in R software version 3.13 (<http://www.r-project.org/>).
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